We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

BioMag Receives Second Patent on Its High Throughput Screening - Magnetic Testing Platform

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

BioMag Corp., through its wholly owned subsidiary Biospectrum Technologies Inc., has announced that it has received its second patent from the U.S. Patent office on its High Throughput Screening - Magnetic Testing Platform (HTS-MTP) that is designed to produce both qualitative (yes/no) and quantitative (viral load) results from a single test.

Clayton Hardman, president and CEO of BioMag Corp., stated, "In addition to the HTS-MTP patent that was received from the U.S. Patent office in July of 2003, we have just received our second patent, further establishing our technology and enabling a broad spectrum of applications in which our product applies, in both medical testing and diagnostics."

"It is safe to say that our product is one of a kind in which can potentially revolutionize the diagnostic industry."